PEP-223

PEP-223 (also referred to as CoVaccine HT) is a peptide-based therapeutic vaccine developed by Pepscan Therapeutics for the treatment of prostate cancer and adenocarcinoma of the prostate. The vaccine is designed as an immunotherapeutic approach to modulate testosterone levels, which are known to drive the progression of prostate cancer cells. It utilizes a specific peptide sequence combined with the CoVaccine HT adjuvant system to induce an immune response. PEP-223 was evaluated in a Phase 1/2 clinical trial (NCT00895466) that commenced in 2009 to assess its safety and efficacy in reducing testosterone levels in men with prostate cancer. While Pepscan Therapeutics partnered with Fusion Pharmaceuticals for peptide-based radiopharmaceutical development, the specific clinical progression of the PEP-223 vaccine program has not been updated in recent public disclosures, leaving its current development status unclear.